Download MendeleyAllosteric Mutant IDH1 Inhibitors Reveal Mechanisms for IDH1 Mutant and Isoform Selectivity.
Xie, X., Baird, D., Bowen, K., Capka, V., Chen, J., Chenail, G., Cho, Y., Dooley, J., Farsidjani, A., Fortin, P., Kohls, D., Kulathila, R., Lin, F., McKay, D., Rodrigues, L., Sage, D., Toure, B.B., van der Plas, S., Wright, K., Xu, M., Yin, H., Levell, J., Pagliarini, R.A.(2017) Structure 25: 506-513
- PubMed: 28132785
- DOI: https://doi.org/10.1016/j.str.2016.12.017
- Primary Citation of Related Structures:
5SUN, 5SVF, 5SVN, 5SVO - PubMed Abstract:
Oncogenic IDH1 and IDH2 mutations contribute to cancer via production of R-2-hydroxyglutarate (2-HG). Here, we characterize two structurally distinct mutant- and isoform-selective IDH1 inhibitors that inhibit 2-HG production. Both bind to an allosteric pocket on IDH1, yet shape it differently, highlighting the plasticity of this site. Oncogenic IDH1 R132H mutation destabilizes an IDH1 "regulatory segment," which otherwise restricts compound access to the allosteric pocket. Regulatory segment destabilization in wild-type IDH1 promotes inhibitor binding, suggesting that destabilization is critical for mutant selectivity. We also report crystal structures of oncogenic IDH2 mutant isoforms, highlighting the fact that the analogous segment of IDH2 is not similarly destabilized. This intrinsic stability of IDH2 may contribute to observed inhibitor IDH1 isoform selectivity. Moreover, discrete residues in the IDH1 allosteric pocket that differ from IDH2 may also guide IDH1 isoform selectivity. These data provide a deeper understanding of how IDH1 inhibitors achieve mutant and isoform selectivity.
Organizational Affiliation:
Center for Proteomic Chemistry, Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA 02139, USA.
